Accelerating Protein Production with Natures Resilience

The Fungi2Pharma project aims to revolutionize the production of pharmaceutical proteins, which are essential for creating life-saving drugs like antibodies, vaccines, and hormones. Traditionally, these proteins are produced using mammalian cell cultures, a process that is slow, expensive, and prone to contamination. The Fungi2Pharma project proposes a groundbreaking solution by using a resilient microorganism called Trichoderma reesei, a type of filamentous fungus, to produce these proteins more quickly and at a lower cost.

Trichoderma reesei has a natural ability to secrete large amounts of proteins, making it an ideal candidate for this purpose. Over the past 40 years, extensive research has been conducted to optimize this fungus for industrial use. The project aims to further enhance its capabilities to produce fully humanized proteins, which are crucial for the pharmaceutical industry.
The main aim of the Fungi2Pharma project is to establish a consortium of Finnish companies to explore the possibilities of using Trichoderma reesei for pharmaceutical protein production. This consortium will work together to create a new value chain and increase the resilience of the Finnish pharmaceutical industry. By combining advanced fungal strains with expertise in pharmaceutical protein production, the project will accelerate the time-to-market, reduce production costs, and simplify the manufacturing process.

The global pharmaceutical market is vast, with biotechnology accounting for a significant portion of total pharmaceutical sales. By leveraging the unique capabilities of Trichoderma reesei, the Fungi2Pharma project aims to disrupt current bio-manufacturing practices and create significant revenue opportunities. This project will also contribute to the establishment of a secure domestic supply chain for therapeutics and vaccine production in Finland.